May 30, 2018 08:12 AM EDT

FDA moves Sage’s postpartum depression drug brexanolone into regulators’ busy priority lane

The FDA’s priority review pathway is getting a workout.

Regulators agreed to give Sage Therapeutics $SAGE a quick 6-month review for IV …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA moves Sage’s post­par­tum de­pres­sion drug brex­anolone in­to reg­u­la­tors’ busy pri­or­i­ty lane